Citation(s)
- Armstrong DG, Lipsky BA, Polis AB, Abramson MA
Does dermal thermometry predict clinical outcome in diabetic foot infection? Analysis of data from the SIDESTEP* trial. Int Wound J. 2006 Dec;3(4):302-7.
- Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA
Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007 Sep;45(9):2819-28.
- Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005 Nov 12;366(949
- Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA
The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDESTEP trial. Wound Repair Regen. 2009 Sep-Oct;17(5):671-7. doi: 10.1111/j.1524-475X.2009.00521.x.
- Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB, Abramson MA
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. Int Wound J. 2007 Mar;4(1):30-8.
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.
Details for clinical trial NCT00229112
